Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00221195 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
A Phase 2 study, sponsored by Tulane University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00221195 is a Phase 2 study that has completed, run by Tulane University School of Medicine. The registered enrollment target is 34 participants.
The verdict
NCT00221195, a Phase 2 study, has completed, sponsored by Tulane University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.
Interventions
- DRUG activated prothrombin complex concentrate (FEIBA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2003-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00221195
The ClinicalTrials.gov registry entry for NCT00221195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which activated prothrombin complex concentrate (FEIBA) is the first listed.
NCT00221195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00221195 about?
NCT00221195 is a clinical study titled "Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors". The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.
What is the current status of trial NCT00221195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2003-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00221195?
The interventions under investigation include: activated prothrombin complex concentrate (FEIBA) (DRUG).
Who is sponsoring clinical trial NCT00221195?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.